Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
135 studies found for:    MUC1
Show Display Options
Rank Status Study
1 Recruiting Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
Conditions: Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Pancreatic Carcinoma;   Triple-Negative Invasive Breast Carcinoma
Intervention: Biological: anti-MUC1 CAR T Cells
2 Completed A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1
Condition: Prostate Cancer
Intervention: Biological: DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1
3 Recruiting CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
Conditions: Malignant Glioma of Brain;   Colorectal Carcinoma;   Gastric Carcinoma
Intervention: Biological: anti-MUC1 CAR-T cells
4 Recruiting CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
Conditions: Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Pancreatic Carcinoma;   Triple-Negative Invasive Breast Carcinoma;   Malignant Glioma of Brain;   Colorectal Carcinoma;   Gastric Carcinoma
Intervention: Biological: anti-MUC1 CAR-pNK cells
5 Completed
Has Results
Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Condition: Risk for Colorectal Cancer
Intervention: Biological: MUC1 - Poly ICLC
6 Not yet recruiting Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.
Condition: Gastric Cancer
Interventions: Biological: MUC1-gene-DC-CTL;   Biological: MUC1-peptide-DC-CTL
7 Completed A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies
Condition: Multiple Myeloma
Intervention: Biological: ImMucin, hGM-CSF
8 Withdrawn A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
Conditions: Multiple Myeloma;   Tumors
Intervention: Biological: Peptide Vaccine (MUC-1)
9 Recruiting Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers
Condition: Epithelial Cancers of the Lung, Breast, Ovary, Prostate and Colon
Intervention: Drug: Ad-sig-hMUC-1/ecdCD40L vector vaccine
10 Completed MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: MUC_1
11 Active, not recruiting Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps
Conditions: Colorectal Adenoma;   Colorectal Adenoma With Severe Dysplasia;   Colorectal Tubulovillous Adenoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: MUC1 Peptide-Poly-ICLC Vaccine;   Other: Quality-of-Life Assessment;   Other: Saline
12 Suspended Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Biological: Vaccine + PolyICLC
13 Terminated Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Biological: MVA-MUC1-IL2
14 Completed Vaccine Therapy in Treating Patients With Breast Cancer
Condition: Breast Cancer
Intervention: Biological: MUC1-KLH vaccine/QS21
15 Recruiting PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC
Conditions: Head and Neck Squamous Cell Carcinoma;   Head and Neck Cancer
Interventions: Drug: Tadalafil;   Biological: Anti-MUC1 Vaccine;   Biological: Anti-Influenza Vaccine;   Other: Tadalafil Placebo;   Other: Vaccine Placebo;   Procedure: Peripheral Blood Collection;   Procedure: DTH Skin Test;   Procedure: Tumor specimen collection
16 Completed Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: MVA-MUC1-IL2;   Drug: 1st line Chemotherapy
17 Active, not recruiting MUC1 Vaccine for Triple-negative Breast Cancer
Conditions: Breast Cancer;   Inflammatory Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Biological: MUC-1 peptide vaccine;   Biological: poly ICLC;   Biological: MUC1 peptide-poly-ICLC adjuvant vaccine;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry
18 Recruiting Nasal Mucin Oral Supplementation Treatment Respiratory Inflammation Using PUFA in Cystic Fibrosis (CF) Patients
Conditions: Cystic Fibrosis;   Dietary Modification
Interventions: Other: polyunsaturated fatty acids n-3;   Other: placebo
19 Withdrawn Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer (NSCLC) Stage III
Interventions: Other: Biological: MUC1 peptide specific immunotherapy;   Drug: Cyclophosphamide (CPA)
20 Recruiting A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia, in Relapse;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: GO-203-2c;   Drug: GO-203-2c + Decitabine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.